Persons with occupational risk for infection 6.
Persons living in, or relocating to, endemic areas 7.
Household and sexual contacts of individuals with acute hepatitis A (with additional gamma globulin in select patients) 8. For all children 9. Unvaccinated persons who anticipate close personal contact with an international adoptee during the first 60 days after arrival in the USA from a country with high or intermediate endemicity
Hepatitis B Inactive viral Intramuscular Three doses at 0, 1, and 6 months Not routinely 1. For all infants antigen, (subcutaneous (see Table A–2 for childhood recommended 2. Preadolescents, adolescents, and young adults recombinant injection is schedule) 3. Persons with occupational, lifestyle, or environmental risk acceptable 4. Diabetic adults <60 years of age 5. Persons with end-stage renal disease, HIV, or chronic liver disease disorders) 6. Postexposure prophylaxis 7. Household and sexual contacts of individuals with acute and chronic hepatitis B Human Virus-like particles Intramuscular Three doses at 0, 4–8, and papillomavirus of the major capsid
Influenza, Inactivated virus or Intramuscular; One dose (Children <9 years who inactivated viral components an intradermal are receiving influenza vaccine vaccine is avail-for the first time should receive able for adults two doses administered at least aged 18–64 years; 4 weeks apart.) a high-dose formulation is an option for adults ≥65 years
None 1. HPV2, HPV4, or HPV9 for females between 9 and 26 years of age; HPV4 or HPV9 for males aged 9–21 years 2.
3.
Yearly with 1. All adults >18 years current vaccine 2. All children aged 6 months to 18 years Influenza, live Live virus Intranasal Split dose in each nostril. Children Yearly with Healthy persons aged 19–49 years who desire protection against attenuated age 5–8 who are receiving influ-current vaccine influenza. May be substituted for inactivated vaccine in healthy enza vaccine for the first time children 2–18 years except (1) asthmatics, and (2) those aged should receive two doses 2–4 years with wheezing in the past year administered 6–10 weeks apart
Measles-Live virus Subcutaneous See Table A–2 None 1. For all children mumps-rubella 2. Adults born after 1956 (MMR)
Meningococcal Bacterial Intramuscular One dose Every 5 years if 1. All adolescents conjugate polysaccharides there is continu-2. Preferred over polysaccharide vaccine in persons aged 11–55 years vaccine conjugated to ing high risk of 3. College freshman aged <22 years who live in dormitories 4.
5.
Individuals with asplenia or complement deficiency (two-dose series) 6.
Microbiologists who are routinely exposed to isolates of Neisseria meningitidis 7.
HIV-positive men who have sex with men
Meningococcal Bacterial Subcutaneous One dose Every 5 years if 1. Adult travelers >55 years to areas with hyperendemic or epidemic polysaccharide polysaccharides there is continu-meningococcal disease vaccine of serotypes ing high risk of A/C/Y/W-135